An Adaptive Design, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections.

Trial Profile

An Adaptive Design, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Fusidic acid (Primary) ; Linezolid
  • Indications Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Skin infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 19 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Sep 2010 Results were presented in an abstract (L1-1762) at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top